An immuno-oncology triplet from Roche shows promise in mouse models of several tumors

Targeting CD40, a receptor on the surface of immune cells, stimulates cancer-killing T cells. University of Basel researchers combined an investigational CD40-targeted antibody from Roche with two of the company's drugs that plug up leaky blood vessels and found that the combo was effective in mouse models of breast, colon and skin cancers.